Costco (NASDAQ:COST) stock is on the move Thursday as investors react to news of an insider selling the company’s shares.
Canton Frates, an executive vice president for Costco, sold 1,200 shares of COST stock on Oct. 6. These shares were sold for an average per share sale price of $562.64.
While Frates sold a decent amount of COST stock with this transaction, the executive still holds a large stake in the company. After the sale, Frates continues to hold 8,362.912 shares of Costco stock.
Investors will also keep in mind that Frates has been buying up shares of COST over the last few months. In the past three months, his insider trading has helped amount to net share ownership of 53,500 shares.
Patrick Callans, another executive vice president at Costco, also recently sold shares. This saw the executive sell 2,500 shares on Oct. 9. These were sold for an average price of $553.76 per share. Callans also continues to hold 67,734.473 shares of COST stock following the sale.
COST Stock Movement on Thursday
Costco investors don’t seem particularly bothered by today’s insider selling news. As of this writing, only about 3,000 shares have changed hands. For comparison, the daily average trading volume for the stock is 1.7 million shares.
COST stock is up slightly as of Thursday morning and was up 24.8% year-to-date (YTD) as of Wednesday’s close.
Investors looking for more of the latest stock market news today are in the right place!
We’re offering up insight into all of the most important stock stories on Thursday. A few examples include what’s going on with shares of Ehang (NASDAQ:EH), Phio Pharma (NASDAQ:PHIO) and Tempest Therapeutics (NASDAQ:TPST) stock today. You can catch up on all of these matters at the links below!
More Stock Market News for Thursday
- Dear Ehang (EH) Stock Fans, Mark Your Calendars for Oct. 13
- Why Is Phio Pharma (PHIO) Stock Down 35% Today?
- Why Is Tempest Therapeutics (TPST) Stock Down 35% Today?
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
